1. Home
  2. GBLI vs TBPH Comparison

GBLI vs TBPH Comparison

Compare GBLI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBLI
  • TBPH
  • Stock Information
  • Founded
  • GBLI 2016
  • TBPH 2013
  • Country
  • GBLI United States
  • TBPH United States
  • Employees
  • GBLI N/A
  • TBPH N/A
  • Industry
  • GBLI Property-Casualty Insurers
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBLI Finance
  • TBPH Health Care
  • Exchange
  • GBLI Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • GBLI 476.1M
  • TBPH 464.5M
  • IPO Year
  • GBLI 2003
  • TBPH N/A
  • Fundamental
  • Price
  • GBLI $30.01
  • TBPH $9.20
  • Analyst Decision
  • GBLI
  • TBPH Buy
  • Analyst Count
  • GBLI 0
  • TBPH 3
  • Target Price
  • GBLI N/A
  • TBPH $11.33
  • AVG Volume (30 Days)
  • GBLI 6.4K
  • TBPH 289.2K
  • Earning Date
  • GBLI 05-07-2025
  • TBPH 05-08-2025
  • Dividend Yield
  • GBLI 4.57%
  • TBPH N/A
  • EPS Growth
  • GBLI N/A
  • TBPH N/A
  • EPS
  • GBLI 1.99
  • TBPH N/A
  • Revenue
  • GBLI $437,447,000.00
  • TBPH $65,266,000.00
  • Revenue This Year
  • GBLI $8.70
  • TBPH $51.09
  • Revenue Next Year
  • GBLI $14.56
  • TBPH N/A
  • P/E Ratio
  • GBLI $15.39
  • TBPH N/A
  • Revenue Growth
  • GBLI N/A
  • TBPH 6.11
  • 52 Week Low
  • GBLI $26.94
  • TBPH $7.44
  • 52 Week High
  • GBLI $37.00
  • TBPH $10.90
  • Technical
  • Relative Strength Index (RSI)
  • GBLI 51.81
  • TBPH 48.37
  • Support Level
  • GBLI $28.82
  • TBPH $8.33
  • Resistance Level
  • GBLI $30.98
  • TBPH $10.55
  • Average True Range (ATR)
  • GBLI 1.11
  • TBPH 0.45
  • MACD
  • GBLI 0.40
  • TBPH -0.11
  • Stochastic Oscillator
  • GBLI 74.15
  • TBPH 39.19

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: